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Abstract
Aims Identification of patients with type 2 diabetes (T2D) at increased risk of incident heart failure (HF) beyond traditional
risk factors such as prior myocardial infarction (MI) might allow selection of patients who would benefit from preventative
treatment. Microvascular disease (MiVD) is thought to play a pathophysiological role in the development of HF in T2D; how-
ever, its association with new-onset HF with reduced or preserved ejection fraction has not been specifically defined.
Methods and results Patients in the Genetics of Diabetes Audit and Research Tayside Scotland study were linked to echo-
cardiography, prescriptions, and clinical outcomes. In total, 9141 patients with T2D were identified for analysis. Clinical vari-
ables and the presence of retinopathy, nephropathy, and neuropathy were assessed. Cumulative incidence was calculated
for the association of both individual and the total number of MiVD states and incident HF. Median follow-up was 9.3 years.
In total, there were 900 HF events. The presence of any MiVD was independently associated with both HF with reduced ejec-
tion fraction (hazard ratio 1.40; 95% confidence interval 1.11–1.76, P = 0.004) and HF with preserved ejection fraction (hazard
ratio 1.38; 95% confidence interval 1.10–1.72, P = 0.005), with a stepwise association between the number of MiVD states and
risk of incident HF (P for trend <0.001). Similar associations were found in sensitivity analyses limited to patients without a
prior MI, and using competing risks analysis.
Conclusions Individuals with T2D and with MiVD are at risk of incident HF independent of a history of prior HF or MI. Pa-
tients with MiVD could benefit from screening for HF and individualized therapy with treatments that lower HF risk.
Keywords Type 2 diabetes; Heart failure; Microvascular disease
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Introduction
Individuals with type 2 diabetes mellitus (T2D) are at high risk
of developing heart failure (HF). Several studies have shown
an HF prevalence of at least 20% in patients with T2D, with
the development of HF being associated with significantly
worse prognosis.1 Commonly, the development of HF in pa-
tients with T2D is attributed to macrovascular disease, with
myocardial ischaemia and infarction leading to HF with re-
duced ejection fraction (HFrEF). T2D itself increases the risk
of HF however that may be independent of coronary artery
disease, myocardial infarction (MI), and other concomitant
conditions such as hypertension.2,3 There is increasing
recognition of the high prevalence of HF with preserved ejec-
tion fraction (HFpEF), which is not always associated with risk
factors such as coronary artery disease but rather may be
caused by the presence of diabetes itself.4,5 The prevalence
of HFpEF in patients with T2D is increasing and now accounts
for almost half of all HF,6 constituting a huge unmet need as
HFpEF currently has no evidence-based therapies.
Sodium-glucose co-transporter 2 inhibitors reduce HF hos-
pitalization in patients with T2D both with and without a his-
tory of HF—indeed, the majority of patients in the
cardiovascular (CV) outcome trials did not have a history of
HF.7–9 Consequently, current guidelines recommend
sodium-glucose co-transporter 2 inhibitors use to lower risk
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of HF hospitalization in patients with T2D.10,11 Given that pa-
tients with T2D are often at high risk of HF even in the ab-
sence of atherosclerotic disease, identification of other risk
factors for incident HF in T2D could allow patients to start
these preventative treatments in a more targeted way before
overt HF develops.
One of the main pathophysiological processes thought to
be implicated in the development of HF in patients with
T2D is microvascular disease (MiVD) which is prevalent in
T2D and may contribute to the development of both HFpEF
and HFrEF.12 Although coronary MiVD is not routinely mea-
sured in clinical practice, T2D screening programmes do as-
sess for the presence of three types of MiVD—retinopathy,
nephropathy, and neuropathy. Both retinopathy13 and ne-
phropathy14 have been independently associated with HF
mortality or hospitalization in observational cohort studies.
There are less data on peripheral neuropathy and HF out-
comes; however, the presence of neuropathy is associated
with worse CV outcome.15 Additionally, the ‘burden’ of MiVD,
that is, the sum of MiVD states, has also been shown to be
associated with CV outcomes.16,17 What is not known is
whether the presence of MiVD is similarly associated with
both HFrEF and HFpEF.
The aim of this study was to determine the independent
association of MiVD with incident HF events in a large cohort
of patients with T2D with available echocardiographic data.
Methods
Cohort derivation
Patients with T2D were identified from the Genetics of Diabe-
tes Audit and Research Tayside Scotland (GoDARTS) registry;
the full details have been published previously.18 In brief,
GoDARTS is an epidemiological cohort study comprising
18 306 participants including 10 149 with T2D and 8157 con-
trols without T2D. Only patients with T2Dwere included in this
study. Baseline data are collected on all patients as well as
blood samples for genotyping, and all patients consent to pro-
spective electronic record linkage for drug prescriptions, blood
samples, retinal screening, and clinical outcomes. For this spe-
cific analysis, study entry and baseline data were taken from
the time of recruitment to GoDARTS. We excluded patients
with an HF hospitalization prior to recruitment. Clinical out-
comes are obtained from the Scottish Mortality andMorbidity
Record while deaths are obtained from the General Records
Office Scotland. Patient data are linked back as far as 1987
through a unique patient number (Community Health Index
number), and the data were available until December 2016.
Collection and analysis of data in GoDARTS were approved
by the East of Scotland Research and Ethics Committee, in
compliance with the declaration of Helsinki.
Assessment of microvascular disease
The current Scottish Intercollegiate Guidelines Network
(SIGN) guideline for management of T2D recommends
that all patients with T2D in Scotland have annual retinal
and foot screening as well as annual measurement of
albumin/creatinine ratio.19 Patients are invited to take part,
and this is typically performed either at the patient’s primary
care physician, a hospital clinic, or optometrist. We were able
to capture this through the patients’ electronic health
records.
The presence of MiVD (retinopathy, nephropathy, and
neuropathy) at the time of recruitment was determined.
The presence of retinopathy was assessed by retinal photog-
raphy and based on the Scottish Diabetic Retinopathy
Grading System,20 which itself is similar to the American
Academy of Ophthalmology International Clinical Disease
System for Diabetic Retinopathy.21 The Scottish system re-
ports diabetic retinopathy in seven categories: R0, no reti-
nopathy; R1, mild background retinopathy; R2, moderate
background; R3, severe background; R4, proliferative; R5,
enucleated; and R6, unable to assess. The highest grade of
the two eyes at the time of photograph was used for this
study. The presence of retinopathy was classified as ≥R1 at
any point prior to recruitment as previously described.22,23
The presence of nephropathy was classified according to
urine albumin/creatinine ratio taken within 24 months of re-
cruitment. If patients had more than one sample taken, the
median value within that time period was taken. Nephropa-
thy was diagnosed if the urine albumin/creatinine ratio was
>30 mg/mmol, that is, severely increased as per the Kidney
Disease Improving Global Outcomes guidelines.24
Neuropathy was assessed using monofilament screening
data, with any abnormal monofilament test classed as the
presence of neuropathy. During each test, a monofilament
is applied to 10 sites on each foot, and a positive result sug-
gestive of neuropathy is recorded if sensation is absent
≥2/5 sites in either foot.25
The total MiVD burden was assessed by summing together
the presence of the three individual MiVD states. As not all
patients had available data on all three MiVD states, we only
analysed MiVD burden in patients who had available data in
all three MiVD beds prior to recruitment.
Other baseline variables
Diagnosis of prior MI and HF hospitalization before study en-
try was made based on ICD-10 coding (I21 and I22 and I50,
respectively). Continuous variables for which there may have
been more than one measurement were taken as the median
value over the 2 years prior to the start date for this study
[body mass index (BMI), total and HDL cholesterol, blood
pressure, haemoglobin A1c (HbA1c), and serum creatinine],
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taking advantage of the longitudinal nature of our electronic
health records to ensure we obtained a more accurate reflec-
tion of clinical status for these variables. Baseline data were
also obtained on use of insulin, duration of diabetes, and his-
tory of smoking at the time of recruitment.
Identification of incident heart failure
Patients included from GoDARTS were linked to the Tayside
echocardiography database which has been described previ-
ously.26 In brief, this database contains data on over
110 000 clinically requested echocardiograms from 1994 on-
wards. Echocardiograms are reported by fully accredited
sonographers (either British Society of Echocardiography or
European Society of Cardiovascular Imaging). This database
has been used previously to determine the presence of left
ventricular systolic dysfunction.26,27
HF outcomes were linked using ICD-10 coding as men-
tioned earlier. Incident HF hospitalization or death was re-
corded if HF was either the primary cause of death or
hospitalization or within the first two secondary causes.
Where echocardiography had been performed, for the pur-
poses of this study, HFrEF was classified as an HF event in a
patient with prior LVEF <50% at any point before the event
(encompassing both HFrEF and HF with mid-range ejection
fraction), while HFpEF was an HF event with LVEF ≥50% and
no previous echocardiography showing LVEF <50%.5,28
Statistical analysis
Continuous variables are reported as mean ± SD or median
(interquartile range) as appropriate while categorical
variables are reported as number (percentage). Kaplan–Meier
and multivariable Cox regression were performed to ascer-
tain the association of MiVD with incident HF overall and
HFpEF and HFrEF following recruitment into GoDARTS. Given
that MI is associated with HF development sensitivity analysis
was performed with the competing risk of MI using the
Fine-Gray model to account for the possibility of individuals
dying or having an MI prior to potential HF development.
Both Cox and competing risk regression models were fully ad-
justed for age; gender; smoking; prior MI; duration of T2D;
BMI; systolic blood pressure; glycosylated haemoglobin
(HbA1c); total and HDL cholesterol; and insulin, statin, and as-
pirin use. We also performed a sub-analysis excluding pa-
tients with a prior MI to determine the association of MiVD
and HF in patients without prior MI. All P values reported
are two sided, and a P value <0.05 was considered signifi-
cant. All statistical analysis was performed using R version
3.5.1.
Results
Baseline characteristics
In total, 9141 patients with T2D were included in the study.
Of these, 5648 (61.8%) had available data on all three MiVD
states at recruitment. Baseline characteristics of the cohort
are summarized in Table 1, while derivation of the dataset
used for analysis is summarized in Figure 1. The mean age
of the cohort was 65 ± 12 years, and 5063 (55.4%) patients
were male. In total, 4182 patients had no MiVD (45.7%). At
baseline, 4239 patients (46.4%) had any retinopathy, 550
(6.0%) had nephropathy, and 1173 (12.8%) had neuropathy.
Table 1 Baseline characteristics
No microvascular disease (n = 4182) Any microvascular disease (n = 4959) P value
Age (years) 63 ± 12 66 ± 12 <0.001
Male 2219 (55.8) 2844 (57.1) <0.001
Median duration of diabetes (years) 3.2 (2.2–4.4) 7.7 (3.2–12.2) <0.001
Smoker 788 (17.6) 736 (15.9) 0.031
Prior myocardial infarction 372 (8.9) 524 (10.6) 0.008
Body mass index (kg/m2) 30.5 ± 6.1 31.2 ± 5.6 <0.001
History of hypertension 1870 (44.7) 2534 (51.1) <0.001
COPD 44 (10.5) 47 (9.5) 0.69
Atrial fibrillation 128 (3.1) 218 (4.4) 0.001
Systolic blood pressure (mmHg) 143 ± 6 144 ± 6 0.67
Insulin use 965 (23.1) 1506 (30.4) <0.001
Metformin use 1586 (37.9) 2290 (46.2) <0.001
Sulfonylurea use 882 (21.1) 1614 (32.5) <0.001
HbA1c (%) 7.5 ± 1.1 7.7 ± 1.1 <0.001
Total cholesterol (mmol/L) 4.57 ± 0.73 4.59 ± 0.8 0.18
HDL cholesterol (mmol/L) 1.26 ± 0.32 1.28 ± 0.34 0.016
Serum creatinine (mmol/L) 89 ± 24 96 ± 33 <0.001
Aspirin 1190 (28.5) 1931 (39.0) <0.001
Statin 1991 (47.6) 2667 (53.8) <0.001
ACEI/ARB 1639 (39.2) 2618 (52.8) <0.001
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; HbA1c,
haemoglobin A1c.
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Of the 5648 patients with available data on all three MiVD
states, 2509 had no MiVD (44.4%), 2450 (43.4%) had one
MiVD, 623 (11.0%) had two MiVD, and 66 (1.2%) had three
MiVD.
Patients with MiVD were older and more likely to be male
than those without MiVD. The presence of MiVD was associ-
ated with significantly longer duration of T2D, reduced likeli-
hood of smoking, higher BMI, lower HDL cholesterol, and
higher HbA1c. MiVD was also associated with increased like-
lihood of prior MI and increased use of cardioprotective med-
ications, insulin, metformin, and sulfonylureas.
Association between microvascular disease and
incident heart failure
Median follow-up was 9.3 years (interquartile range 4.8–
14.1 years). In total, there were 900 individuals who had an
incident HF event (including 51 HF deaths and 858 HF hospi-
talizations; 11.1% of the total cohort). Of these, 366 were
classified as HFrEF events and 382 as HFpEF events, with
the remaining 109 unclassified as no echocardiogram was
available.
After adjusting for relevant baseline variables (age, gender,
duration of diabetes, insulin, metformin, sulfonylurea and
angiotensin-converting enzyme inhibitor/angiotensin recep-
tor blocker use, prior MI, HbA1c, HDL and total cholesterol,
systolic blood pressure, serum creatinine, smoking status,
and body mass index) the presence of any MiVD was
independently associated with incident HF (hazard ratio, HR
1.39; 95% CI, confidence interval 1.20–1.61, P < 0.001). In
the same fully adjusted model, all individual MiVD states
were also independently associated with incident HF (reti-
nopathy: HR 1.33; 95% CI 1.16–1.53, P < 0.001; neuropathy:
HR 1.23; 95% CI 1.03–1.47, P = 0.022; nephropathy: HR 1.60;
95% CI 1.26–2.03; P< 0.001) (Table 2 and Figure 2). These re-
sults were similar when analysed taking into account compet-
ing risk of MI, with significant associations between the
presence of any MiVD, retinopathy and nephropathy, and in-
cident HF. In the 5648 patients who had available data on all
three MiVD states at baseline, there was also a stepwise
trend seen with increased number of MiVD states present be-
ing associated with increasing risk of incident HF (one MiVD:
HR 1.42; 95% CI 1.16–1.74, P < 0.001; two or three MiVD: HR
1.98; 95% CI 1.53–2.56, P < 0.001, P for trend <0.001).
In the whole cohort, after adjustment for all baseline vari-
ables, the presence of MiVD was independently associated
with both HFrEF (HR 1.40; 95% CI 1.11–1.76, P = 0.004) and
HFpEF (HR 1.38; 95% CI 1.10–1.72, P = 0.005) (Table 3). There
remained a stepwise association between the number of
MiVD states at baseline and incident HFrEF (one MiVD: HR
1.65; 95% CI 1.19–2.27, P = 0.003; two or three MiVD: HR
2.41; 95% CI 1.62–3.60, P < 0.001, P for trend <0.001). Pa-
tients with two or three MiVD states were more likely to de-
velop incident HFpEF than those with no or one MiVD (one
MiVD: HR 1.25; 95% CI 0.91–1.71, P = 0.16; two or three
MiVD: HR 1.85; 95% CI 1.24–2.75, P = 0.002, P for
trend = 0.003) (Figure 3).
Figure 1 Cohort derivation. Derivation of the study cohort from the Genetics of Diabetes Audit and Research Tayside Scotland (GoDARTS) dataset.
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Table 2 Association between microvascular disease and incident heart failure
Multivariable cox regression
Adjustment for competing
risk of MI
Microvascular disease
Number of events/number
at risk (%)
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
Any microvascular disease 899/9141 (9.8) 1.39 (1.20–1.61) <0.001 1.27 (1.08–1.50) 0.005
Retinopathy 892/9043 (9.9) 1.33 (1.16–1.53) <0.001 1.19 (1.01–1.40) 0.034
Neuropathy 835/7882 (10.6) 1.23 (1.03–1.47) 0.022 1.17 (0.96–1.44) 0.12
Nephropathy 588/6804 (8.6) 1.60 (1.26–2.03) <0.001 1.82 (1.39–2.38) <0.001
Number of microvascular disease states
0 153/2509 (6.1) Baseline Baseline
1 258/2450 (10.5) 1.42 (1.16–1.74) <0.001 1.26 (0.99–1.59) 0.061
2/3 116/689 (16.8) 1.98 (1.53–2.56) <0.001 1.77 (1.31–2.39) <0.001
Adjusted for age, sex, duration of diabetes, insulin use, sulfonylurea use, metformin use, angiotensin-converting enzyme inhibitor/angio-
tensin receptor blocker use, prior myocardial infarction, haemoglobin A1c, HDL and total cholesterol, systolic blood pressure, serum cre-
atinine, smoking status, and body mass index. CI, confidence interval.
Figure 2 Microvascular disease burden incident heart failure. Kaplan–Meier curves demonstrating the association between microvascular disease and
incident heart failure.
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Association between microvascular disease and
heart failure in patients without a history of
myocardial infarction
After excluding the 896 patients with a prior MI, 8245 individ-
uals remained for analysis. In this sub-cohort, the presence of
any MiVD remained significantly associated with incident HF
(HR 1.36; 95% CI 1.16–1.60, P < 0.001). The presence of
MiVD was significantly associated with both HFrEF (HR 1.34;
95% CI 1.04–1.74, P = 0.026) and HFpEF (HR 1.38; 95% CI
1.08–1.75, P = 0.010) (Supporting Information, Table S1).
Both retinopathy (HR 1.31; 95% CI 1.12–1.52, P < 0.001)
and nephropathy (HR 1.67; 95% CI 1.28–2.17, P < 0.001)
were significantly associated with incident HF, while there
was also a non-significant association between neuropathy
and increased risk of incident HF (HR 1.22; 95% CI 1.00–
1.49, P = 0.054). There was a stepwise association between
the number of MiVD states present and increased risk of inci-
dent HF (one MiVD: HR 1.38; 95% CI 1.10–1.74, P = 0.005;
two or three MiVD: HR 1.71; 95% CI 1.10–1.74, P < 0.001;
P for trend <0.001). A similar trend was found for the associ-
ation between number of MiVD states and incident HFrEF
(one MiVD: HR 1.54; 95% CI 1.06–2.24, P = 0.022; two or
three MiVD: HR 2.02; 95% CI 1.26–3.23, P = 0.004; P for trend
<0.001). Patients with two or three MiVD were at particularly
increased risk of HFpEF (HR 1.75; 95% CI 1.12–2.73,
P = 0.0173).
Discussion
In this large observational cohort study of individuals with
T2D without a prior history of HF, we have shown that the
presence of any MiVD is independently associated with inci-
dent HF, including HFrEF and HFpEF, after adjustment for
multiple clinical variables, including prior MI, duration of dia-
betes, and glycaemic control and independent of the compet-
ing risk of incident MI. We have also shown that the burden
of MiVD (measured by the number of MiVD states present)
is significantly associated with increased risk of HF in a step-
wise manner. Finally, we have shown that the association be-
tween MiVD and HF is present even in patients without a
history of MI, and in particular, the presence of MiVD is
Table 3 Association between microvascular disease and heart failure with reduced and preserved ejection fraction
HFrEF HFpEF
Number of
events/available patients
Hazard ratio
(95% CI) P value
Number of
events/available patients
Hazard ratio
(95% CI) P value
No microvascular disease 121/4182 (2.9) Baseline 130/4182 (3.1) Baseline
Any microvascular disease 245/4959 (4.9) 1.40 (1.11–1.76) 0.004 252/4959 (5.1) 1.38 (1.10–1.72) 0.005
Number of microvascular disease states
0 59/2493 (2.4) Baseline 71/2493 (2.8) Baseline
1 114/2417 (4.7) 1.65 (1.19–2.27) 0.003 100/2417 (4.1) 1.25 (0.91–1.71) 0.16
2/3 50/674 (7.4) 2.41 (1.62–3.60) <0.001 47/674 (7.0) 1.85 (1.24–2.75) 0.002
Adjusted for age, sex, duration of diabetes, insulin use, sulfonylurea use, metformin use, angiotensin-converting enzyme inhibitor/angio-
tensin receptor blocker use, prior myocardial infarction, haemoglobin A1c, HDL and total cholesterol, systolic blood pressure, smoking
history, and body mass index. CI, confidence interval; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction.
Figure 3 Number of microvascular disease states and risk of heart failure. Kaplan–Meier curves demonstrating the association between the number of
microvascular disease states present and risk of incident heart failure (HF), HF with reduced ejection fraction (HFrEF), and HF with preserved ejection
fraction (HFpEF).
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associated with increased risk of HF. These results would sug-
gest that the presence of MiVD may also be considered an in-
dependent risk factor for HF and may be used by clinicians in
individualized selection of diabetes therapy.
Several previous cohort studies have shown that individual
features of MiVD are associated with development of HF in pa-
tients with T2D. A cohort study of 1021 patients by Cheung
et al.13 reported the independent association of retinopathy
with incident HF. Nephropathy has also been independently
associated with development of HF.29 There are limited data
on neuropathy; however, it has been associated with compos-
ite CV outcomes.15 A large study of patients >65 years also
identified that retinopathy, nephropathy, and neuropathy
were all independently associated with development of HF;
however, the study did not adjust for many factors which
could modify HF risk including HbA1c, duration of T2D, blood
pressure, and medication use.17 Importantly, our study ex-
tends these findings by using echocardiographic data, allowing
us to show for the first time that the association between
MiVD and HF is present in HFrEF and HFpEF. Additionally, we
have used a competing risk regression model to increase the
robustness of our findings. One possible explanation for our
findings is that the presence of MiVD may simply be a surro-
gate for macrovascular disease risk, leading to MI and subse-
quent HF. Our analysis suggests however that MiVD is itself a
risk factor for HF independent of a prior history of MI.
To the best of our knowledge, our study is the first to show
that MiVD is also associated with incident HFpEF as well as
HFrEF. T2D is itself associated with a number of structural ab-
normalities such as left ventricular hypertrophy, a common
finding in HFpEF which is thought to be of pathophysiological
importance.30,31 Recent studies have shown that MiVD in pa-
tients with T2D and diagnosed HFpEF is highly prevalent and
associated with HF severity and worse outcome32; however,
ours is the first to show the independent prognostic associa-
tion between MiVD and development of HFpEF. Echocardio-
graphic studies have shown that T2D is associated with
abnormalities of diastolic function independent of the pres-
ence of coronary artery disease.33,34 In addition, the presence
of MiVD in patients with T2D also seems to be associated
with the presence of diastolic dysfunction.35–37 It is possible
that MiVD plays a role in the pathophysiology of incident
HFpEF but, perhaps more importantly, that MiVD is a risk fac-
tor for development of HFpEF. This is of particular importance
as HFpEF accounts for almost half of all HF in individuals with
T2D and, at present, does not have any evidence-based
treatment.38
Our finding that the increased burden of MiVD is associ-
ated with a stepwise increase in risk of HF also mirrors the
findings from a large cohort study published recently.16 In
this study of almost 50 000 individuals with over 2000 events,
the authors reported an increased relative risk of 32% for
those with one MiVD, 62% for those with two MiVD, and
99% for those with three MiVD for the combined primary
outcome of CV death and non-fatal MI or stroke. Our study
confirms this similar pattern for both HFrEF and HFpEF.
Although our results only show association, they do raise
the possibility that MiVD may be a risk factor that could be
used to identify individuals with T2D in whom overt HF could
be prevented. Coronary MiVD measured invasively using cor-
onary flow reserve has also been shown to be associated with
risk of HFpEF independent of coronary artery disease39 and is
associated with increased severity of HF in patients with a di-
agnosis of HFpEF.40 This MiVD may lead to inflammation and
fibrosis, thus predisposing to HFpEF.41,42 A recent imaging
study found that the presence of coronary MiVD in patients
with T2D defined as reduced myocardial perfusion in the ab-
sence of significant epicardial coronary stenosis was associ-
ated with structural and functional abnormalities that could
lead to HF.43 The hyperinsulinaemic state associated with
T2D and MiVD also plays a role in increasing HF risk.43,44 Tra-
ditionally, prevention of MiVD has been through strict
glycaemic control; however, previous trials of pure
glucose-lowering therapies such as sulfonylureas and insulin
have not shown any CV benefit over the duration of the stud-
ies.45,46 It may be however that other mechanisms, for exam-
ple, insulin resistance, oxidative stress, and metabolic
changes, which are associated with MiVD are also important
in development of HF.3,47
The major clinical implication of our work might be the use
of the presence of MiVD as a screening tool to identify pa-
tients at risk of HF in the absence of other traditional risk fac-
tors such as MI, hypertension, and hyperlipidaemia. This
would be of particular interest given the recent positioning
of SGLT2 inhibitors as preferred treatments in patients with
T2D at high-risk of HF rather than other therapies that have
demonstrated CV risk reduction such as glucagon-like
peptide-1 receptor agonists.10,11 While features such as the
presence of left ventricular dysfunction or history of prior
MI would certainly place patients at high-risk of HF, many pa-
tients with T2D without these features remain at high-risk of
incident HF. Of the major SGLT2 outcome trials, only CANVAS
had mention of MiVD (albuminuria) as one of the inclusion
criteria in patients without established atherosclerotic cardio-
vascular disease.9 Our work also shows that patients with
neuropathy and retinopathy are also at high risk of incident
HF and may be used to help identify patients who might ben-
efit from these therapies.
The major SGLT2 outcome trials in patients with T2D only
included ~10% of patients with a history of HF, and the CV risk
reduction was similar regardless of the presence of HF at base-
line. A recent post hoc analysis of the EMPA-REG trial also
reported that the presence of MiVD was associated with in-
creased risk of HF hospitalization and that empagliflozin caused
a significant HF risk reduction compared to placebo.48 More
recently, the results of the DAPA-HF trial in HFrEF patients dem-
onstrated a reduction in mortality and HF hospitalization re-
gardless of T2D status.49 Clinicians might consider watching
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for signs of HF or undertaking echocardiography in patients
with MiVD who might benefit from targeted treatment with
SGLT2 inhibitors to prevent HF hospitalization.38 This is impor-
tant as it has been identified that less than half of all patients
with T2D and HF meet the current US Food and Drug Adminis-
tration criteria for prescribing of SGLT2 inhibitors.50
Our study does have some limitations. First, due to its ob-
servational nature, we are not able to definitively prove cau-
sality of MiVD with HF. Nevertheless, a strength of our study
is its large cohort size and the adjustment for several con-
founders using longitudinal data, as well as using a competing
risk regression model. Second, our definition of HFpEF was
pragmatic, based on the nature of routine clinical reports,
which often omit other diagnostic features of HFpEF such as
left atrial size and mitral inflow velocities. Additionally, as
measurement of natriuretic peptides is not routinely available
in Scotland, this provided a further limitation.
Conclusions
Microvascular disease (MiVD) is independently associated
with both incident HFrEF and HFpEF in patients with T2D,
even in patients without prior MI. Patients with MiVD may
be considered at high-risk of incident HF and may benefit
from screening for HF and individualized therapy decisions
with treatment aimed at prevention of HF.
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